{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T19:02:01Z","timestamp":1769281321926,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04493-4","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:28:29Z","timestamp":1769228909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"91","author":[{"given":"Muhammad","family":"Umais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooriah","family":"Imtiaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Luqman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidra","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Umer","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwal","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarine Tasnim","family":"Sara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor ul","family":"Huda Naseem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firose Afra","family":"Ibnath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rehman Shah","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ali","family":"Muzammil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"4493_CR1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Definition & facts for NAFLD & NASH. National Institute of Diabetes and Digestive and Kidney Diseases. https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts. Accessed May 23, 2025."},{"issue":"1","key":"4493_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Z.M. Younossi, A.B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, M. Wymer, Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73\u201384 (2016). https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"issue":"6","key":"4493_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","volume":"164","author":"VL Chen","year":"2023","unstructured":"V.L. Chen, A. Oliveri, M.J. Miller, K. Wijarnpreecha, X. Du, Y. Chen, K.C. Cushing, A.S. Lok, E.K. Speliotes, PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology 164(6), 966\u2013977.e17 (2023). https:\/\/doi.org\/10.1053\/j.gastro.2023.01.040","journal-title":"Gastroenterology"},{"issue":"12","key":"4493_CR4","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"S. Romeo, J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L.A. Pennacchio, E. Boerwinkle, J.C. Cohen, H.H. Hobbs, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40(12), 1461\u20131465 (2008). https:\/\/doi.org\/10.1038\/ng.257","journal-title":"Nat. Genet."},{"key":"4493_CR5","unstructured":"Johns Hopkins Medicine. Nonalcoholic fatty liver disease. Johns Hopkins Medicine. https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/nonalcoholic-fatty-liver-disease. Accessed May 23, 2025."},{"issue":"4","key":"4493_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/1573403X1604201229115531","volume":"16","author":"P Farmaki","year":"2020","unstructured":"P. Farmaki, C. Damaskos, N. Garmpis, A. Garmpi, S. Savvanis, E. Diamantis, Complications of the type 2 diabetes mellitus. Curr. Cardiol. Rev. 16(4), 249\u2013251 (2020). https:\/\/doi.org\/10.2174\/1573403X1604201229115531","journal-title":"Curr. Cardiol. Rev."},{"issue":"1","key":"4493_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"M.A.B. Khan, M.J. Hashim, J.K. King, R.D. Govender, H. Mustafa, J. Al Kaabi, Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends. J. Epidemiol. Glob. Health 10(1), 107\u2013111 (2020). https:\/\/doi.org\/10.2991\/jegh.k.191028.001","journal-title":"J. Epidemiol. Glob. Health"},{"issue":"1","key":"4493_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12933-025-02793-7","volume":"24","author":"YS Lyu","year":"2025","unstructured":"Y.S. Lyu, M. Park, H.K. Kim, S. Park, J.Y. Park, A.R. Hong, J.H. Yoon, S. Jeong, Y. Yoon, J.H. Kim, S.Y. Kim, H.C. Kang, W. Choi, Combined impact of prediabetes and fatty liver index on cardiometabolic outcomes and mortality in middle aged adults: a nationwide cohort study. Cardiovasc. Diabetol. 24(1), 279 (2025). https:\/\/doi.org\/10.1186\/s12933-025-02793-7","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"4493_CR9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s12072-023-10542-9","volume":"17","author":"A Ramandi","year":"2023","unstructured":"A. Ramandi, J. George, S. Merat, E. Jafari, M. Sharafkhah, A.R. Radmard, A. Nateghi Baygi, A. Delavari, Z. Mohammadi, H. Poustchi, R. Malekzadeh, Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatol. Int. 17(4), 882\u2013888 (2023). https:\/\/doi.org\/10.1007\/s12072-023-10542-9","journal-title":"Hepatol. Int."},{"issue":"24","key":"4493_CR10","doi-asserted-by":"publisher","first-page":"17147","DOI":"10.3390\/ijms242417147","volume":"24","author":"R Weinberg Sibony","year":"2023","unstructured":"R. Weinberg Sibony, O. Segev, S. Dor, I. Raz, Drug therapies for diabetes. Int. J. Mol. Sci. 24(24), 17147 (2023). https:\/\/doi.org\/10.3390\/ijms242417147","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"4493_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2337\/dc20-1964","volume":"44","author":"A Giaccari","year":"2021","unstructured":"A. Giaccari, A. Solini, S. Frontoni, S. Del Prato, Metformin benefits: another example for alternative energy substrate mechanism? Diabetes Care 44(3), 647\u2013654 (2021). https:\/\/doi.org\/10.2337\/dc20-1964","journal-title":"Diabetes Care"},{"issue":"5","key":"4493_CR12","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/jcm12051852","volume":"12","author":"M Kosmalski","year":"2023","unstructured":"M. Kosmalski, R. Frankowski, S. Zi\u00f3\u0142kowska, M. R\u00f3\u017cycka-Kosmalska, T. Pietras, What\u2019s new in the treatment of non-alcoholic fatty liver disease (NAFLD). J. Clin. Med. 12(5), 1852 (2023). https:\/\/doi.org\/10.3390\/jcm12051852","journal-title":"J. Clin. Med."},{"key":"4493_CR13","unstructured":"American Diabetes Association. Understanding type 2 diabetes. American Diabetes Association. https:\/\/diabetes.org\/about-diabetes\/type-2. Accessed May 23, 2025."},{"issue":"39","key":"4493_CR14","doi-asserted-by":"publisher","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","volume":"96","author":"W Dai","year":"2017","unstructured":"W. Dai, L. Ye, A. Liu et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine 96(39), e8179 (2017). https:\/\/doi.org\/10.1097\/MD.0000000000008179","journal-title":"Medicine"},{"key":"4493_CR15","volume-title":"Clinical review report: Empagliflozin (Jardiance) [Internet]","author":"Canadian Agency for Drugs and Technologies in Health","year":"2015","unstructured":"Canadian Agency for Drugs and Technologies in Health. Clinical review report: Empagliflozin (Jardiance) [Internet]. (Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)), 2015. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534176\/ Oct. Appendix 1, Patient Input Summary. Available from:"},{"issue":"1","key":"4493_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.gastro.2020.03.039","volume":"159","author":"ZM Younossi","year":"2020","unstructured":"Z.M. Younossi, A.B. Koenig, D. Abdelatif et al. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 159(1), 1\u201313.e1 (2020). https:\/\/doi.org\/10.1053\/j.gastro.2020.03.039","journal-title":"Gastroenterology"},{"key":"4493_CR17","volume-title":"StatPearls [Internet]","author":"O Sizar","year":"2025","unstructured":"O. Sizar, V. Podder, R. Talati. Empagliflozin. [Updated 2023 May 29]. StatPearls [Internet]. (StatPearls Publishing, Treasure Island (FL)), 2025). Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532925\/"},{"issue":"3","key":"4493_CR18","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"M.J. Page, J.E. McKenzie, P.M. Bossuyt et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 18(3), e1003583 (2021). https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med."},{"key":"4493_CR19","unstructured":"Higgins J.P.T., Thomas J., Chandler J., et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3. Cochrane; 2022. Available from: www.training.cochrane.org\/handbook,"},{"key":"4493_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron, C.J. Cates, H.Y. Cheng, M.S. Corbett, S.M. Eldridge, J.R. Emberson, M.A. Hern\u00e1n, S. Hopewell, A. Hr\u00f3bjartsson, D.R. Junqueira, P. J\u00fcni, J.J. Kirkham, T. Lasserson, T. Li, A. McAleenan, J.P.T. Higgins, RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019). https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"7414","key":"4493_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327(7414), 557\u2013560 (2003). https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"3","key":"4493_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"H. Chehrehgosha, M.R. Sohrabi, F. Ismail-Beigi et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 12(3), 843\u2013861 (2021). https:\/\/doi.org\/10.1007\/s13300-021-01011-3","journal-title":"Diabetes Ther."},{"issue":"1","key":"4493_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","volume":"20","author":"B Gaborit","year":"2021","unstructured":"B. Gaborit, P. Ancel, A.E. Abdullah et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc. Diabetol. 20(1), 57 (2021). https:\/\/doi.org\/10.1186\/s12933-021-01237-2","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"4493_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"S. Kahl, S. Gancheva, K. Stra\u00dfburger et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43(2), 298\u2013305 (2020). https:\/\/doi.org\/10.2337\/dc19-0641","journal-title":"Diabetes Care"},{"issue":"8","key":"4493_CR25","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"M.S. Kuchay, S. Krishan, S.K. Mishra et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41(8), 1801\u20131808 (2018). https:\/\/doi.org\/10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"issue":"12","key":"4493_CR26","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/ph15121516","volume":"15","author":"SH Elhini","year":"2022","unstructured":"S.H. Elhini, E.A. Wahsh, A.A. Elberry et al. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals 15(12), 1516 (2022). https:\/\/doi.org\/10.3390\/ph15121516","journal-title":"Pharmaceuticals"},{"issue":"2","key":"4493_CR27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53813","volume":"16","author":"E Koullias","year":"2024","unstructured":"E. Koullias, M. Papavdi, S. Athanasopoulos et al. Addition of dulaglutide or empagliflozin to standard-of-care treatment: effect on liver steatosis in patients with type 2 diabetes mellitus. Cureus 16(2), e53813 (2024). https:\/\/doi.org\/10.7759\/cureus.53813","journal-title":"Cureus"},{"issue":"4","key":"4493_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40261-016-0383-1","volume":"36","author":"T Ohki","year":"2016","unstructured":"T. Ohki, A. Isogawa, N. Toda, K. Tagawa, Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin. Drug. Investig. 36(4), 313\u2013319 (2016)","journal-title":"Clin. Drug. Investig."},{"issue":"1-3","key":"4493_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"A. Tahara, E. Kurosaki, M. Yokono et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 715(1-3), 246\u2013255 (2013)","journal-title":"Eur. J. Pharmacol."},{"issue":"9733","key":"4493_CR30","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, J.F. List, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733), 2223\u20132233 (2010)","journal-title":"Lancet"},{"issue":"3","key":"4493_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"J. Bolinder, \u00d6. Ljunggren, J. Kullberg et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97(3), 1020\u20131031 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4493_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/DMSO.S58786","volume":"7","author":"SP Vickers","year":"2014","unstructured":"S.P. Vickers, S.C. Cheetham, K.R. Headland et al. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab. Syndr. Obes. Targets Ther. 7, 265\u2013275 (2014)","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"4493_CR33","first-page":"817","volume":"15","author":"MR McGill","year":"2016","unstructured":"M.R. McGill, The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 15, 817\u2013828 (2016)","journal-title":"EXCLI J."},{"issue":"10","key":"4493_CR34","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","volume":"61","author":"N Sattar","year":"2018","unstructured":"N. Sattar, D. Fitchett, S. Hantel, J.T. George, B. Zinman, Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial. Diabetologia 61(10), 2155\u20132163 (2018)","journal-title":"Diabetologia"},{"issue":"3","key":"4493_CR35","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/edm2.131","volume":"3","author":"V Mittag-Roussou","year":"2020","unstructured":"V. Mittag-Roussou, S. Wagenpfeil, F. Lammert, C.S. Stokes, Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. Endocrinol. Diabetes Metab. 3(3), e00131 (2020)","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"4","key":"4493_CR36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"K. Cusi, F. Bril, D. Barb et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes. Metab. 21(4), 812\u2013821 (2019)","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"4493_CR37","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"J.W. Eriksson, P. Lundkvist, P.A. Jansson et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61(9), 1923\u20131934 (2018)","journal-title":"Diabetologia"},{"issue":"11","key":"4493_CR38","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"H. Taheri, M. Malek, F. Ismail-Beigi et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv. Ther. 37(11), 4697\u20134708 (2020)","journal-title":"Adv. Ther."},{"issue":"22","key":"4493_CR39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117\u20132128 (2015)","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"4493_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/14740338.2016.1135900","volume":"15","author":"IJ Neeland","year":"2016","unstructured":"I.J. Neeland, U. Salahuddin, D.K. McGuire, A safety evaluation of empagliflozin for the treatment of type 2 diabetes. Expert. Opin. Drug. Saf. 15(3), 393\u2013402 (2016)","journal-title":"Expert. Opin. Drug. Saf."},{"issue":"6","key":"4493_CR41","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","volume":"38","author":"S Kohler","year":"2016","unstructured":"S. Kohler, A. Salsali, S. Hantel et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin. Ther. 38(6), 1299\u20131313 (2016)","journal-title":"Clin. Ther."},{"issue":"3","key":"4493_CR42","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc14-2364","volume":"38","author":"RA DeFronzo","year":"2015","unstructured":"R.A. DeFronzo, A. Lewin, S. Patel et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38(3), 384\u2013393 (2015)","journal-title":"Diabetes Care"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04493-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04493-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04493-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:28:31Z","timestamp":1769228911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04493-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4493"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04493-4","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no conflict of interest among the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"49"}}